HOME  >  Online journal

Vol.45 No.3 contents

Japanese/English

Full Text of PDF (264K) Article in Japanese

- -

Induction Chemoradiotherapy for c-N2 Non-Small Cell Lung Cancer

Hiroyasu Yokomise¹, Taku Okamoto¹, Cheng-Long Huang¹, Yasumichi Yamamoto¹, Shinya Ishikawa¹, Takashi Nakashima¹, Daiki Masuya¹, Masashi Gotoh¹, Dage Liu¹, Jiro Fujita², Shuji Bandoh², Toshihiko Ishida², Shinichi Sumitomo^3
1Second Department of Surgery, ²First Department of Internal Medicine, Kagawa University School of Medicine, Japan, ³Department of Thoracic Surgery, Japanese Red Cross Wakayama Medical Center, Japan

---

Objectives. The therapeutic results for c-N2 non-small cell lung cancer(NSCLC) are extremely bad. To improve these results, we performed induction chemoradiotherapy (ICRT). Materials and methods. 50 patients with c-N2 NSCLC underwent operation following ICRT from January 1992 to April 2004. Until 1998, MVP (mitomycin C, vindesine, cisplatin) or EP (etoposide, cisplatin) (n=27, group-A). After that, Taxan+CBDCA (carboplatin) (Tx+P) (n=23, group-B). Two cycles of chemotherapy were performed with concurrent radiation (50 Gy). Results. In all 50 cases, complete resection was performed with no operative mortality. Response rate was 74%. Histological response rate of Ef 2 or Ef 3 was 78% (38 cases of 50 cases). Complete histological response was observed in 10 cases (20%). Three-year survival was 54%. Three-year survival of Ef 3 patients in group B (Tx+p) was 80% and three patients survived more than 40 months. Conclusions. Surgery after ICRT for c-N2 NSCLC could be performed safely with promising results. Better outcome is anticipated for patients who exhibit good histological response.
key words: c-N2 non-small cell lung cancer (NSCLC), Induction chemoradiotherapy (ICRT), Pathological effect

JJLC 45 (3): 275-279, 2005